$IOVA 🗞️AstraZeneca is discontinuing a late-stage trial of volrustomig plus chemotherapy in metastatic NSCLC patients whose tumours lack PD-L1 expression.
To be clear, AstraZeneca continues to report positive results from other NSCLC trials and remains highly active in the
